Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated risk of mortality in its ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug ...

Black Diamond Therapeutics shows promise with BDTX-1535 for NSCLC treatment. Click here to find out why I rate BDTX stock a ...

Lissencephaly is a spectrum of rare, genetic disorders in which the brain fails to develop its hallmark folds. The disorders ...

This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...